Nano-X Imaging (NNOX) expanded its U.S. distribution network through an agreement with Associated X-Ray Imaging to market, distribute and support Nanox.ARC across New England. The FDA-cleared 3D digital tomosynthesis system will gain access to additional outpatient and community clinical settings through the distributor's regional sales and service network.
Nano-X Imaging Ltd. (NNOX) revealed Loss for first quarter of -$14.265 million The company's bottom line totaled -$14.265 million, or -$0.20 per share. This compares with -$13.239 million, or -$0.21 per share, last year. Excluding items, Nano-X Imaging Ltd. reported adjusted earnings of -$11.131...
Below are the earnings highlights for Nano-X Imaging Ltd. (NNOX): Earnings: -$33.37 million in Q4 vs. -$14.06 million in the same period last year. EPS: -$0.50 in Q4 vs. -$0.23 in the same period last year. Excluding items, Nano-X Imaging Ltd. reported adjusted earnings of $11.19 million or $0.17...
Nano-X Imaging Ltd. (NNOX) announced on Wednesday that it has agreed to acquire VasoHealthcare IT Inc. from Vaso Corporation (VASO), a move aimed at accelerating the rollout of its AI-driven medical imaging solutions across U.S. healthcare systems.
Nano-X Imaging Ltd. (NNOX), Thursday announced that it has received 510(k) clearance from the U.S. Food and Drug Administration or FDA for its Nanox.ARC X, a new multi-source digital tomosynthesis system designed for general clinical use. The clearance allows the Nanox.ARC X to produce tomographic...
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.